Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas

[1]  I. Petersen,et al.  Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. , 2020, JAMA oncology.

[2]  A. Stein,et al.  Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Blay,et al.  Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. , 2020, The Lancet. Oncology.

[4]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[5]  B. Morland,et al.  Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma , 2019, Annals of Oncology.

[6]  M. Sydes,et al.  Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort , 2019, European journal of cancer.

[7]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[8]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  D. Hawkins,et al.  Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Robin L. Jones,et al.  Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Blay,et al.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.

[12]  E. Voest,et al.  Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours , 2015, British Journal of Cancer.

[13]  J. Blay,et al.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.

[14]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[15]  S. Baruchel,et al.  Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor , 2011, Clinical Cancer Research.

[16]  R. Kerbel,et al.  Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer , 2009, Molecular Cancer Therapeutics.

[17]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[18]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[19]  C. Bokemeyer,et al.  An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma , 2003, Investigational New Drugs.

[20]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[21]  J. Folkman.  Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[22]  M. Bernstein,et al.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Mannel,et al.  Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. , 2000, American journal of clinical oncology.

[24]  M. van Glabbeke,et al.  Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Karakousis,et al.  Soft tissue sarcomas in adults , 1994, CA: a cancer journal for clinicians.